Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407YS | ISIN: US8162123025 | Ticker-Symbol: 1S70
München
24.04.25
08:08 Uhr
10,300 Euro
0,000
0,00 %
1-Jahres-Chart
CARTESIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARTESIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,30010,70018:47

Aktuelle News zur CARTESIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients1
08.04.Cartesian Therapeutics, Inc.: Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial108After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest...
► Artikel lesen
08.04.Cartesian Therapeutics, Inc. - 8-K, Current Report1
02.04.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants97FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapies for the treatment of...
► Artikel lesen
CARTESIAN THERAPEUTICS Aktie jetzt für 0€ handeln
17.03.Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics3
17.03.Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright5
13.03.Cartesian Therapeutics GAAP EPS of -$4.49 beats by $1.38, revenue of $38.91M misses by $0.83M3
13.03.Cartesian Therapeutics, Inc. - 10-K, Annual Report1
13.03.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update134Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial...
► Artikel lesen
13.03.Cartesian Therapeutics, Inc. - 8-K, Current Report3
06.03.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant112FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
03.03.Cartesian Therapeutics, Inc. - 8-K, Current Report1
06.02.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants115FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
27.01.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis192FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases...
► Artikel lesen
27.01.Cartesian Therapeutics, Inc. - 8-K, Current Report-
13.01.Cartesian Therapeutics, Inc. - 8-K, Current Report3
07.01.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants163FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
18.12.24Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants118FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
► Artikel lesen
03.12.24Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial142Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of =3 points...
► Artikel lesen
03.12.24Cartesian Therapeutics, Inc. - 8-K, Current Report-
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1